FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149573022> ?p ?o ?g. }

• W2149573022 endingPage "722" @default.
• W2149573022 startingPage "712" @default.
• W2149573022 abstract "Background. Resistance to antiretroviral combination therapy is associated with increased mortality. Understanding the relative risks of emerging resistance to first-line therapy is of importance for both resource-rich and resource-poor settings. Methods. We undertook an overview of clinical trials of adults receiving first-line highly active antiretroviral therapy (HAART), which consisted of dual nucleoside reverse-transcriptase inhibitors (NRTIs) combined with a third agent (either a nonnucleoside reverse-transcriptase inhibitor [NNRTI] or a ritonavir-boosted protease inhibitor [bPI]). The primary outcome measures were incidences of mutations conferring resistance to key drugs (NRTIs, NNRTIs, or bPIs) per trial at week 48. For meta-analysis, inverse-variance weighting was used to create estimates of overall incidences per group, with exact 95% confidence intervals (95% CIs). Results. The study included 20 clinical trials that comprised 30 treatment arms and 7970 patients. Virologic failure at 48 weeks occurred in 4.9% (95% CI, 3.9%–6.1%) of NNRTI recipients, compared with 5.3% (95% CI, 4.4%–6.4%; P=.50) of bPI recipients. Of failures that were successfully genotyped, the M184V mutation in the HIV reverse transcriptase (lamivudine resistance) occurred in 35.3% (95% CI, 29.3%–41.6%) of patients who started NNRTI-based HAART, compared with 21.0% (95% CI, 14.4%–28.8%; P<.001) for those who received a bPI. For the K65R mutation in the HIV reverse transcriptase (multinucleoside resistance), incidences were 5.3% (95% CI, 2.4%–9.9%) and 0.0% (95% CI, 0.0%–3.6%; P=.01), respectively, in patients treated with non-zidovudine-containing regimens. Resistance to the third agent (an NNRTI or PI) occurred in 53% (95% CI, 46%–60%) and 0.9% (95% CI, 0.0%–6.2%; P<.001) of such patients, respectively. Conclusions. Initial therapy with bPI-based regimens resulted in less resistance within and across drug classes. This finding is of particular significance for the developing world, where rates of resistance to NRTIs and NNRTIs at 48 weeks are much higher than has been seen in both cohorts and clinical trials in well-resourced countries." @default.
• W2149573022 created "2016-06-24" @default.
• W2149573022 creator A5017146733 @default.
• W2149573022 creator A5036869978 @default.
• W2149573022 creator A5054475275 @default.
• W2149573022 creator A5059988483 @default.
• W2149573022 date "2008-09-01" @default.
• W2149573022 modified "2023-10-16" @default.
• W2149573022 title "Emergence of Drug Resistance in HIV Type 1–Infected Patients after Receipt of First‐Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials" @default.
• W2149573022 cites W1967825197 @default.
• W2149573022 cites W1971758213 @default.
• W2149573022 cites W1994491237 @default.
• W2149573022 cites W1995019918 @default.
• W2149573022 cites W1997141231 @default.
• W2149573022 cites W2000495412 @default.
• W2149573022 cites W2016257631 @default.
• W2149573022 cites W2032039529 @default.
• W2149573022 cites W2032312237 @default.
• W2149573022 cites W2041308498 @default.
• W2149573022 cites W2046689230 @default.
• W2149573022 cites W2052332986 @default.
• W2149573022 cites W2052991207 @default.
• W2149573022 cites W2056779298 @default.
• W2149573022 cites W2057977668 @default.
• W2149573022 cites W2061857819 @default.
• W2149573022 cites W2080734162 @default.
• W2149573022 cites W2083477796 @default.
• W2149573022 cites W2086182786 @default.
• W2149573022 cites W2088221871 @default.
• W2149573022 cites W2098740488 @default.
• W2149573022 cites W2103866977 @default.
• W2149573022 cites W2109350540 @default.
• W2149573022 cites W2110937893 @default.
• W2149573022 cites W2122280827 @default.
• W2149573022 cites W2124801504 @default.
• W2149573022 cites W2128327031 @default.
• W2149573022 cites W2141776019 @default.
• W2149573022 cites W2165762745 @default.
• W2149573022 cites W2170578204 @default.
• W2149573022 cites W2318289184 @default.
• W2149573022 cites W2416045060 @default.
• W2149573022 doi "https://doi.org/10.1086/590943" @default.
• W2149573022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18662137" @default.
• W2149573022 hasPublicationYear "2008" @default.
• W2149573022 type Work @default.
• W2149573022 sameAs 2149573022 @default.
• W2149573022 citedByCount "174" @default.
• W2149573022 countsByYear W21495730222012 @default.
• W2149573022 countsByYear W21495730222013 @default.
• W2149573022 countsByYear W21495730222014 @default.
• W2149573022 countsByYear W21495730222015 @default.
• W2149573022 countsByYear W21495730222016 @default.
• W2149573022 countsByYear W21495730222017 @default.
• W2149573022 countsByYear W21495730222018 @default.
• W2149573022 countsByYear W21495730222019 @default.
• W2149573022 countsByYear W21495730222021 @default.
• W2149573022 countsByYear W21495730222023 @default.
• W2149573022 crossrefType "journal-article" @default.
• W2149573022 hasAuthorship W2149573022A5017146733 @default.
• W2149573022 hasAuthorship W2149573022A5036869978 @default.
• W2149573022 hasAuthorship W2149573022A5054475275 @default.
• W2149573022 hasAuthorship W2149573022A5059988483 @default.
• W2149573022 hasBestOaLocation W21495730221 @default.
• W2149573022 hasConcept C104317684 @default.
• W2149573022 hasConcept C114851261 @default.
• W2149573022 hasConcept C126322002 @default.
• W2149573022 hasConcept C142462285 @default.
• W2149573022 hasConcept C156719811 @default.
• W2149573022 hasConcept C159047783 @default.
• W2149573022 hasConcept C182707283 @default.
• W2149573022 hasConcept C2522874641 @default.
• W2149573022 hasConcept C2777351918 @default.
• W2149573022 hasConcept C2777869810 @default.
• W2149573022 hasConcept C2778451633 @default.
• W2149573022 hasConcept C2779465607 @default.
• W2149573022 hasConcept C2779889181 @default.
• W2149573022 hasConcept C2780216070 @default.
• W2149573022 hasConcept C2780593183 @default.
• W2149573022 hasConcept C2780727368 @default.
• W2149573022 hasConcept C2993143319 @default.
• W2149573022 hasConcept C3013748606 @default.
• W2149573022 hasConcept C44249647 @default.
• W2149573022 hasConcept C49105822 @default.
• W2149573022 hasConcept C55493867 @default.
• W2149573022 hasConcept C71924100 @default.
• W2149573022 hasConcept C86803240 @default.
• W2149573022 hasConcept C89423630 @default.
• W2149573022 hasConceptScore W2149573022C104317684 @default.
• W2149573022 hasConceptScore W2149573022C114851261 @default.
• W2149573022 hasConceptScore W2149573022C126322002 @default.
• W2149573022 hasConceptScore W2149573022C142462285 @default.
• W2149573022 hasConceptScore W2149573022C156719811 @default.
• W2149573022 hasConceptScore W2149573022C159047783 @default.
• W2149573022 hasConceptScore W2149573022C182707283 @default.
• W2149573022 hasConceptScore W2149573022C2522874641 @default.
• W2149573022 hasConceptScore W2149573022C2777351918 @default.
• W2149573022 hasConceptScore W2149573022C2777869810 @default.
• W2149573022 hasConceptScore W2149573022C2778451633 @default.

• next